PeptiDream Inc. (4587.T)
JPY 2603.5
(-0.53%)
JPY 2603.5
(-0.53%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 28.71 Billion JPY | 6.93% |
| 2022 | 26.85 Billion JPY | 186.7% |
| 2021 | 9.36 Billion JPY | -19.79% |
| 2020 | 11.67 Billion JPY | 462.85% |
| 2019 | 2.07 Billion JPY | -71.25% |
| 2018 | 7.21 Billion JPY | 12.29% |
| 2017 | 6.42 Billion JPY | 31.27% |
| 2016 | 4.89 Billion JPY | 13.12% |
| 2015 | 4.32 Billion JPY | 74.9% |
| 2014 | 2.47 Billion JPY | 202.17% |
| 2013 | 818.9 Million JPY | 20.73% |
| 2012 | 678.26 Million JPY | 152.14% |
| 2011 | 269 Million JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 31.9 Billion JPY | 655.2% |
| 2024 Q1 | 4.22 Billion JPY | -31.5% |
| 2023 Q1 | 4.96 Billion JPY | -68.27% |
| 2023 Q2 | 4.46 Billion JPY | -10.09% |
| 2023 Q3 | 13.11 Billion JPY | 193.95% |
| 2023 Q4 | 6.16 Billion JPY | -52.98% |
| 2023 FY | 28.71 Billion JPY | 6.93% |
| 2022 FY | 26.85 Billion JPY | 186.7% |
| 2022 Q4 | 15.64 Billion JPY | 152.97% |
| 2022 Q2 | 1.43 Billion JPY | 243.04% |
| 2022 Q1 | 419.52 Million JPY | -73.83% |
| 2022 Q3 | 6.18 Billion JPY | 329.71% |
| 2021 Q4 | 1.6 Billion JPY | -67.3% |
| 2021 FY | 9.36 Billion JPY | -19.79% |
| 2021 Q2 | 4.6 Billion JPY | 215.61% |
| 2021 Q3 | 4.9 Billion JPY | 6.46% |
| 2021 Q1 | 1.45 Billion JPY | -81.4% |
| 2020 Q1 | 393.78 Million JPY | 0.0% |
| 2020 FY | 11.67 Billion JPY | 462.85% |
| 2020 Q4 | 7.84 Billion JPY | 981.82% |
| 2020 Q3 | 725.11 Million JPY | -73.28% |
| 2020 Q2 | 2.71 Billion JPY | 589.2% |
| 2019 Q1 | 907 Million JPY | -38.03% |
| 2019 Q2 | 4.29 Billion JPY | 373.03% |
| 2019 FY | 2.07 Billion JPY | -71.25% |
| 2019 Q3 | 394.87 Million JPY | -90.8% |
| 2018 Q2 | 5.28 Billion JPY | 2262.18% |
| 2018 Q3 | 555.63 Million JPY | -89.5% |
| 2018 Q1 | 223.93 Million JPY | -69.82% |
| 2018 Q4 | 1.46 Billion JPY | 163.41% |
| 2018 FY | 7.21 Billion JPY | 12.29% |
| 2017 FY | 6.42 Billion JPY | 31.27% |
| 2017 Q4 | 741.89 Million JPY | 332.86% |
| 2017 Q3 | 171.39 Million JPY | -95.07% |
| 2017 Q2 | 3.47 Billion JPY | 1272.26% |
| 2017 Q1 | 253.48 Million JPY | -31.06% |
| 2016 FY | 4.89 Billion JPY | 13.12% |
| 2016 Q3 | 796.2 Million JPY | -51.64% |
| 2016 Q4 | 367.66 Million JPY | -53.82% |
| 2016 Q2 | 1.64 Billion JPY | -0.02% |
| 2016 Q1 | 1.64 Billion JPY | 155.12% |
| 2015 Q3 | 389.2 Million JPY | -79.93% |
| 2015 FY | 4.32 Billion JPY | 74.9% |
| 2015 Q2 | 1.93 Billion JPY | 1211.38% |
| 2015 Q1 | 147.85 Million JPY | -40.0% |
| 2015 Q4 | 645.49 Million JPY | 65.85% |
| 2014 Q1 | 129.35 Million JPY | -55.91% |
| 2014 Q4 | 246.43 Million JPY | 74.4% |
| 2014 Q3 | 141.3 Million JPY | -36.24% |
| 2014 Q2 | 221.63 Million JPY | 71.33% |
| 2014 FY | 2.47 Billion JPY | 202.17% |
| 2013 FY | 818.9 Million JPY | 20.73% |
| 2013 Q2 | 193.79 Million JPY | 0.0% |
| 2013 Q3 | 174.49 Million JPY | -9.96% |
| 2013 Q4 | 293.42 Million JPY | 68.16% |
| 2012 FY | 678.26 Million JPY | 152.14% |
| 2011 FY | 269 Million JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 4.77 Billion JPY | -501.921% |
| PRISM BioLab Co.,LTD | 112.92 Million JPY | -25325.672% |
| GNI Group Ltd. | 26.01 Billion JPY | -10.387% |
| Linical Co., Ltd. | 12.3 Billion JPY | -133.283% |
| Trans Genic Inc. | 13.08 Billion JPY | -119.454% |
| MEDINET Co., Ltd. | 661.54 Million JPY | -4240.186% |
| Soiken Holdings Inc. | 5.15 Billion JPY | -456.604% |
| Cytori Cell Research Institute, Inc. | 1.56 Billion JPY | -1740.068% |
| AnGes, Inc. | 152.98 Million JPY | -18667.98% |
| OncoTherapy Science, Inc. | 610.11 Million JPY | -4606.007% |
| Nxera Pharma Co., Ltd. | 12.76 Billion JPY | -124.911% |
| Immuno-Biological Laboratories Co., Ltd. | 816.7 Million JPY | -3415.631% |
| NanoCarrier Co., Ltd. | 135.5 Million JPY | -21088.56% |
| Carna Biosciences, Inc. | 1.62 Billion JPY | -1665.938% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 428.36 Million JPY | -6602.756% |
| RaQualia Pharma Inc. | 1.9 Billion JPY | -1410.213% |
| Chiome Bioscience Inc. | 682.46 Million JPY | -4107.137% |
| Kidswell Bio Corporation | 2.43 Billion JPY | -1080.972% |
| Oncolys BioPharma Inc. | 63.03 Million JPY | -45447.438% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | - JPY | -Infinity% |
| Healios K.K. | 121 Million JPY | -23629.086% |
| BrightPath Biotherapeutics Co., Ltd. | 72 Thousand JPY | -39877947.222% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 39.88 Million JPY | -71883.839% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 4.51 Billion JPY | -536.557% |
| FunPep Company Limited | 530 Thousand JPY | -5417295.094% |
| Kringle Pharma, Inc. | 69.25 Million JPY | -41361.652% |
| Stella Pharma Corporation | 269.49 Million JPY | -10554.231% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | 316.81 Million JPY | -8962.678% |
| Cuorips Inc. | 23.1 Million JPY | -124184.452% |
| K Pharma,Inc. | 1 Billion JPY | -2771.219% |
| Takara Bio Inc. | 43.5 Billion JPY | 34.003% |
| ReproCELL Incorporated | 2.42 Billion JPY | -1083.122% |
| PhoenixBio Co., Ltd. | 1.71 Billion JPY | -1573.867% |
| StemCell Institute Inc. | 2.48 Billion JPY | -1057.193% |
| Japan Tissue Engineering Co., Ltd. | 2.51 Billion JPY | -1042.006% |
| CellSeed Inc. | 190.13 Million JPY | -15001.031% |